Discover 920 paid clinical trials in Portland, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 920
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
for
Locally Advanced Cervical Adenocarcinoma,
Location: Portland OR, Clackamas OR, Tualatin OR, Oregon City OR,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07061977
Phase3, Recruiting
Physical Therapy After Endometriosis Excision
for
Endometriosis, Surgery
Location: Portland OR
Sponsor: Oregon Health and Science University
Sex: Female
Age: 18 - 50
Code: NCT07127783
Recruiting
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
for
X-Linked Myotubular Myopathy
Location: Portland OR, Dallas TX, Chicago IL, Toronto, Boston MA
Sponsor: Astellas Gene Therapies
Sex: Male
Age: 0 - 3
Code: NCT07052929
Phase1, Phase2, Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
for
Hemolytic Disease of the Fetus and Newborn
Location: Portland OR, Houston TX, Cincinnati OH, Rochester NY
Sponsor: Janssen Research & Development, LLC
Sex: Female
Age: 18+
Code: NCT07194070
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
for
Malignant Neoplasm
Location: Portland OR, Calgary, Salt Lake City UT, Los Angeles CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 0 - 17
Code: NCT06941272
Phase1, Phase2, Recruiting
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
for
Thrombocytopenia, Neonatal Alloimmune
Location: Portland OR, Sacramento CA, Salt Lake City UT,
Sponsor: Janssen Research & Development, LLC
Sex: Female
Age: 18 - 45
Code: NCT06533098
Phase3, Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia